Flexion Therapeutics Stock Price, News & Analysis (NASDAQ:FLXN)

$23.19 -1.39 (-5.66 %)
(As of 02/19/2018 08:54 AM ET)
Previous Close$24.58
Today's Range$23.17 - $24.75
52-Week Range$16.51 - $32.25
Volume633,100 shs
Average Volume704,997 shs
Market Capitalization$870.57 million
P/E RatioN/A
Dividend YieldN/A
Beta0.91

About Flexion Therapeutics (NASDAQ:FLXN)

Flexion Therapeutics logoFlexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company's lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid. The Company is developing Zilretta as a treatment for patients with moderate to severe OA knee pain. The Company has specifically designed Zilretta to combine a steroid, triamcinolone acetonide (TCA) with poly lactic-co-glycolic acid (PLGA), for providing sustained therapeutic concentrations in the joint and persistent analgesic effect. The Company's other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Company is engaged in conducting a Phase IIb clinical trial of Zilretta.

Receive FLXN News and Ratings via Email

Sign-up to receive the latest news and ratings for FLXN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FLXN
CUSIPN/A
Phone781-305-7777

Debt

Debt-to-Equity Ratio0.87%
Current Ratio12.93%
Quick Ratio12.93%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$6.01 per share
Price / Book3.86

Profitability

Trailing EPS($3.51)
Net Income$-71,890,000.00
Net MarginsN/A
Return on Equity-60.29%
Return on Assets-38.08%

Miscellaneous

Employees95
Outstanding Shares37,540,000

Flexion Therapeutics (NASDAQ:FLXN) Frequently Asked Questions

What is Flexion Therapeutics' stock symbol?

Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."

How were Flexion Therapeutics' earnings last quarter?

Flexion Therapeutics Inc (NASDAQ:FLXN) released its quarterly earnings results on Wednesday, August, 3rd. The specialty pharmaceutical company reported ($0.63) earnings per share for the quarter, topping analysts' consensus estimates of ($0.67) by $0.04. View Flexion Therapeutics' Earnings History.

Where is Flexion Therapeutics' stock going? Where will Flexion Therapeutics' stock price be in 2018?

9 brokers have issued 1 year price objectives for Flexion Therapeutics' stock. Their forecasts range from $37.00 to $570.00. On average, they expect Flexion Therapeutics' share price to reach $99.11 in the next year. View Analyst Ratings for Flexion Therapeutics.

Who are some of Flexion Therapeutics' key competitors?

Who are Flexion Therapeutics' key executives?

Flexion Therapeutics' management team includes the folowing people:

  • Patrick J. Mahaffy, Chairman of the Board (Age 54)
  • Michael D. Clayman M.D., President, Chief Executive Officer, Co-Founder, Director (Age 65)
  • Neil Bodick M.D., Ph.D., Chief Scientific Officer (Age 70)
  • Mark Levine, Vice President, General Counsel (Age 43)
  • John Magee, Vice President - Sales
  • Mark Fraga, Vice President - Marketing
  • Dan Thornton, Vice President - Market Access
  • Scott Kelley M.D., Chief Medical Officer
  • Mark P. Stejbach, Director (Age 53)
  • Scott A. Canute, Independent Director (Age 57)

Who owns Flexion Therapeutics stock?

Flexion Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Gilder Gagnon Howe & Co. LLC (9.99%), Bank of New York Mellon Corp (7.39%), BlackRock Inc. (7.06%), Wells Fargo & Company MN (4.55%), Wasatch Advisors Inc. (1.79%) and Peregrine Capital Management LLC (1.77%). Company insiders that own Flexion Therapeutics stock include C Ann Merrifield, Frederick W Driscoll, Mark Stejbach, Michael D Clayman, Neil Bodick, Samuel D Colella and Yamo Deniz. View Institutional Ownership Trends for Flexion Therapeutics.

Who sold Flexion Therapeutics stock? Who is selling Flexion Therapeutics stock?

Flexion Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Gilder Gagnon Howe & Co. LLC, Cadence Capital Management LLC, Teachers Retirement System of The State of Kentucky, Verde Servicos Internacionais S.A., Metropolitan Life Insurance Co. NY, Monarch Partners Asset Management LLC and Royce & Associates LP. Company insiders that have sold Flexion Therapeutics company stock in the last year include Frederick W Driscoll and Neil Bodick. View Insider Buying and Selling for Flexion Therapeutics.

Who bought Flexion Therapeutics stock? Who is buying Flexion Therapeutics stock?

Flexion Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, BlackRock Inc., Perceptive Advisors LLC, Ardsley Advisory Partners, American Financial Group Inc., Gagnon Securities LLC, Allianz Asset Management GmbH and Bank of New York Mellon Corp. Company insiders that have bought Flexion Therapeutics stock in the last two years include C Ann Merrifield, Frederick W Driscoll, Mark Stejbach, Michael D Clayman, Neil Bodick, Samuel D Colella and Yamo Deniz. View Insider Buying and Selling for Flexion Therapeutics.

How do I buy Flexion Therapeutics stock?

Shares of Flexion Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Flexion Therapeutics' stock price today?

One share of Flexion Therapeutics stock can currently be purchased for approximately $23.19.

How big of a company is Flexion Therapeutics?

Flexion Therapeutics has a market capitalization of $870.57 million. The specialty pharmaceutical company earns $-71,890,000.00 in net income (profit) each year or ($3.51) on an earnings per share basis. Flexion Therapeutics employs 95 workers across the globe.

How can I contact Flexion Therapeutics?

Flexion Therapeutics' mailing address is 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803. The specialty pharmaceutical company can be reached via phone at 781-305-7777 or via email at [email protected]


MarketBeat Community Rating for Flexion Therapeutics (FLXN)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  301 (Vote Outperform)
Underperform Votes:  132 (Vote Underperform)
Total Votes:  433
MarketBeat's community ratings are surveys of what our community members think about Flexion Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Flexion Therapeutics (NASDAQ:FLXN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.892.883.003.13
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $99.11$106.25$98.33$32.34
Price Target Upside: 338.74% upside342.89% upside309.89% upside47.85% upside

Flexion Therapeutics (NASDAQ:FLXN) Consensus Price Target History

Price Target History for Flexion Therapeutics (NASDAQ:FLXN)

Flexion Therapeutics (NASDAQ:FLXN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/1/2018Berenberg BankInitiated CoverageBuy$42.00HighView Rating Details
11/10/2017Northland SecuritiesReiterated RatingBuy$40.00N/AView Rating Details
10/30/2017Wells Fargo & CoSet Price TargetBuy$39.00N/AView Rating Details
10/29/2017Royal Bank of CanadaSet Price TargetBuy$44.00N/AView Rating Details
10/10/2017LaidlawReiterated RatingBuy$35.00 -> $38.00N/AView Rating Details
10/10/2017Janney Montgomery ScottBoost Price TargetBuy -> Fair Value$570.00N/AView Rating Details
10/9/2017BMO Capital MarketsReiterated RatingOutperform$35.00 -> $37.00N/AView Rating Details
10/9/2017Needham & Company LLCBoost Price TargetBuy -> Buy$36.00 -> $42.00N/AView Rating Details
6/12/2017Cantor FitzgeraldSet Price TargetBuy$40.00LowView Rating Details
12/22/2016Raymond James FinancialInitiated CoverageStrong-Buy$35.00N/AView Rating Details
11/8/2016BCSLower Price Target$0.65 -> $0.02N/AView Rating Details
9/6/2016Lake Street CapitalReiterated RatingBuy$38.00N/AView Rating Details
(Data available from 2/19/2016 forward)

Earnings

Flexion Therapeutics (NASDAQ:FLXN) Earnings History and Estimates Chart

Earnings by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Flexion Therapeutics (NASDAQ FLXN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017Q3 2017($0.98)($1.07)ViewN/AView Earnings Details
8/8/2017Q2 2017($0.80)($0.91)ViewListenView Earnings Details
5/4/2017Q1 2017($0.73)($0.75)ViewListenView Earnings Details
3/9/2017Q4 2016($0.71)($0.79)ViewListenView Earnings Details
11/7/2016Q3($0.63)($0.65)ViewListenView Earnings Details
8/3/2016Q2($0.67)($0.63)ViewN/AView Earnings Details
5/12/2016Q1($0.61)($0.78)ViewListenView Earnings Details
3/10/2016Q4 2015($0.58)($0.63)ViewN/AView Earnings Details
11/9/2015Q3($0.60)($0.52)ViewListenView Earnings Details
8/6/2015Q215($0.54)($0.58)ViewN/AView Earnings Details
5/7/2015Q115($0.56)($0.43)ViewN/AView Earnings Details
3/23/2015Q4 2014($0.46)($0.47)ViewN/AView Earnings Details
11/13/2014Q314($0.54)($0.45)ViewN/AView Earnings Details
8/7/2014Q2 2014($0.55)($0.38)ViewN/AView Earnings Details
5/8/2014Q1 2014($0.53)($0.86)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Flexion Therapeutics (NASDAQ:FLXN) Earnings Estimates

Current Year EPS Consensus Estimate: $-3.84 EPS
Next Year EPS Consensus Estimate: $-4.12 EPS

Dividends

Dividend History for Flexion Therapeutics (NASDAQ:FLXN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Flexion Therapeutics (NASDAQ FLXN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 15.98%
Institutional Ownership Percentage: 80.47%
Insider Trades by Quarter for Flexion Therapeutics (NASDAQ:FLXN)
Insider Trades by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Flexion Therapeutics (NASDAQ FLXN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/21/2017Neil BodickInsiderBuy2,700$24.49$66,123.0064,605View SEC Filing  
11/8/2017Michael D ClaymanInsiderBuy5,000$23.60$118,000.0035,395View SEC Filing  
9/5/2017Yamo DenizInsiderBuy1,000$24.20$24,200.005,000View SEC Filing  
9/1/2017Yamo DenizInsiderBuy3,000$24.15$72,450.005,000View SEC Filing  
8/31/2017Yamo DenizInsiderBuy1,375$25.40$34,925.005,000View SEC Filing  
6/16/2017Mark StejbachDirectorBuy1,580$17.02$26,891.60View SEC Filing  
6/5/2017Michael D ClaymanInsiderBuy5,000$17.23$86,150.0020,146View SEC Filing  
4/17/2017Neil BodickInsiderSell5,000$28.23$141,150.0046,137View SEC Filing  
3/23/2017Frederick W DriscollCFOSell3,000$23.00$69,000.0010,777View SEC Filing  
3/17/2017Neil BodickInsiderSell5,000$20.41$102,050.0050,937View SEC Filing  
2/24/2017Neil BodickInsiderSell5,000$19.15$95,750.0055,937View SEC Filing  
1/20/2017Neil BodickInsiderSell5,000$18.35$91,750.0060,937View SEC Filing  
12/21/2016Neil BodickInsiderSell10,000$18.46$184,600.0065,937View SEC Filing  
12/1/2016Samuel D ColellaDirectorBuy10,000$16.38$163,800.0025,504View SEC Filing  
11/23/2016Michael D ClaymanInsiderBuy1,667$18.41$30,689.4730,721View SEC Filing  
11/22/2016Michael D ClaymanInsiderBuy1,666$17.95$29,904.7029,054View SEC Filing  
11/21/2016Michael D ClaymanInsiderBuy1,666$17.90$29,821.4027,388View SEC Filing  
11/21/2016Samuel D ColellaDirectorBuy33,333$18.00$599,994.0025,504View SEC Filing  
6/21/2016Samuel D ColellaDirectorBuy25,504$13.71$349,659.843,435View SEC Filing  
6/20/2016Samuel D ColellaDirectorBuy6,778$13.84$93,807.523,435View SEC Filing  
6/14/2016C Ann MerrifieldDirectorBuy1,000$13.39$13,390.002,000View SEC Filing  
6/8/2016Samuel D ColellaDirectorBuy714,285$14.00$9,999,990.00View SEC Filing  
5/20/2016Michael D ClaymanCEOBuy2,000$10.41$20,820.0013,568View SEC Filing  
5/19/2016Michael D ClaymanCEOBuy2,000$9.65$19,300.0011,568View SEC Filing  
5/19/2016Neil BodickInsiderBuy850$10.00$8,500.0075,937View SEC Filing  
5/18/2016Michael D ClaymanCEOBuy2,000$10.23$20,460.009,568View SEC Filing  
5/18/2016Neil BodickInsiderBuy2,100$10.20$21,420.0075,087View SEC Filing  
5/17/2016Frederick W DriscollCFOBuy2,500$9.87$24,675.008,434View SEC Filing  
5/17/2016Michael D ClaymanCEOBuy2,000$9.73$19,460.007,568View SEC Filing  
5/17/2016Neil BodickInsiderBuy800$9.60$7,680.0072,987View SEC Filing  
5/16/2016Frederick W DriscollCFOBuy2,500$9.19$22,975.005,934View SEC Filing  
5/16/2016Michael D ClaymanCEOBuy2,000$9.51$19,020.005,568View SEC Filing  
5/16/2016Neil BodickInsiderBuy1,250$9.22$11,525.0071,937View SEC Filing  
9/11/2015C Ann MerrifieldDirectorBuy1,000$23.00$23,000.001,000View SEC Filing  
6/22/2015A/S NovoMajor ShareholderSell150,000$20.61$3,091,500.00View SEC Filing  
3/16/2015Neil BodickInsiderSell4,000$25.28$101,120.00View SEC Filing  
3/10/2015Neil BodickInsiderSell4,000$24.26$97,040.00View SEC Filing  
3/4/2015Neil BodickInsiderSell4,000$23.45$93,800.00View SEC Filing  
2/26/2015Neil BodickInsiderSell4,000$22.44$89,760.00View SEC Filing  
12/17/2014A/S NovoMajor ShareholderBuy500,000$17.00$8,500,000.00View SEC Filing  
2/18/2014A/S NovoInsiderBuy692,308$13.00$9,000,004.00View SEC Filing  
2/18/2014Bradley J Phd BolzonDirectorBuy307,692$13.00$3,999,996.00View SEC Filing  
2/18/2014Sofinnova Partners SasMajor ShareholderBuy230,769$13.00$2,999,997.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Flexion Therapeutics (NASDAQ FLXN) News Headlines

Source:
DateHeadline
Flexion Therapeutics to Present at the RBC Capital Markets 2018 Global Healthcare ConferenceFlexion Therapeutics to Present at the RBC Capital Markets 2018 Global Healthcare Conference
finance.yahoo.com - February 14 at 5:11 PM
Flexion Therapeutics Inc (FLXN) Expected to Announce Quarterly Sales of $1.29 MillionFlexion Therapeutics Inc (FLXN) Expected to Announce Quarterly Sales of $1.29 Million
www.americanbankingnews.com - February 9 at 4:48 AM
Flexion Therapeutics Inc (FLXN) Receives Average Rating of "Buy" from BrokeragesFlexion Therapeutics Inc (FLXN) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - February 6 at 5:24 PM
Top Analyst Upgrades and Downgrades: AMD, Caterpillar, Chipotle, eBay, Facebook, Microsoft, Sirius XM, Starbucks and MoreTop Analyst Upgrades and Downgrades: AMD, Caterpillar, Chipotle, eBay, Facebook, Microsoft, Sirius XM, Starbucks and More
www.msn.com - February 1 at 9:40 AM
Flexion Therapeutics (FLXN) Lowered to Sell at Zacks Investment ResearchFlexion Therapeutics (FLXN) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - January 30 at 11:18 PM
Traders Purchase Large Volume of Flexion Therapeutics Put Options (FLXN)Traders Purchase Large Volume of Flexion Therapeutics Put Options (FLXN)
www.americanbankingnews.com - January 26 at 1:40 AM
Flexion Therapeutics Inc (FLXN) Expected to Post Earnings of -$1.09 Per ShareFlexion Therapeutics Inc (FLXN) Expected to Post Earnings of -$1.09 Per Share
www.americanbankingnews.com - January 21 at 7:18 AM
Flexion Therapeutics (FLXN) Downgraded by BidaskClub to "Strong Sell"Flexion Therapeutics (FLXN) Downgraded by BidaskClub to "Strong Sell"
www.americanbankingnews.com - January 20 at 10:28 AM
Flexion Therapeutics Inc (FLXN) Given Average Rating of "Buy" by BrokeragesFlexion Therapeutics Inc (FLXN) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 12 at 5:54 PM
Flexion Therapeutics (FLXN) Reports Initial Data from Clinical Trial Evaluating Repeat Administration of ZILRETTA ... - StreetInsider.comFlexion Therapeutics (FLXN) Reports Initial Data from Clinical Trial Evaluating Repeat Administration of ZILRETTA ... - StreetInsider.com
www.streetinsider.com - January 8 at 5:28 PM
Flexion Therapeutics Announces Initial Data from Clinical Trial Evaluating Repeat Administration of ZILRETTA™ (triamcinolone acetonide extended-release injectable suspension)Flexion Therapeutics Announces Initial Data from Clinical Trial Evaluating Repeat Administration of ZILRETTA™ (triamcinolone acetonide extended-release injectable suspension)
finance.yahoo.com - January 8 at 9:46 AM
3 Biotechs Launching Their First Commercial Drugs in 20183 Biotechs Launching Their First Commercial Drugs in 2018
finance.yahoo.com - January 6 at 9:28 AM
Zacks: Brokerages Anticipate Flexion Therapeutics Inc (FLXN) Will Announce Quarterly Sales of $1.29 MillionZacks: Brokerages Anticipate Flexion Therapeutics Inc (FLXN) Will Announce Quarterly Sales of $1.29 Million
www.americanbankingnews.com - January 6 at 4:48 AM
Flexion Therapeutics (FLXN) versus Sucampo Pharmaceuticals (SCMP) Head to Head ReviewFlexion Therapeutics (FLXN) versus Sucampo Pharmaceuticals (SCMP) Head to Head Review
www.americanbankingnews.com - December 24 at 9:33 PM
Flexion Therapeutics Inc (FLXN) Receives Consensus Rating of "Buy" from AnalystsFlexion Therapeutics Inc (FLXN) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - December 18 at 7:56 PM
Flexion Therapeutics Enrolls First Patient in Study Evaluating the Pharmacokinetics and Safety of ZILRETTA™ (triamcinolone acetonide extended-release injectable suspension) in Osteoarthritis of the Shoulder and HipFlexion Therapeutics Enrolls First Patient in Study Evaluating the Pharmacokinetics and Safety of ZILRETTA™ (triamcinolone acetonide extended-release injectable suspension) in Osteoarthritis of the Shoulder and Hip
finance.yahoo.com - December 18 at 5:22 PM
Flexion Therapeutics (FLXN) Buys Novel, Non-Opioid Asset for Osteoarthritis of the Knee - StreetInsider.comFlexion Therapeutics (FLXN) Buys Novel, Non-Opioid Asset for Osteoarthritis of the Knee - StreetInsider.com
www.streetinsider.com - December 14 at 5:54 PM
Flexion Therapeutics (FLXN) Buys Novel, Non-Opioid Asset for Osteoarthritis of the KneeFlexion Therapeutics (FLXN) Buys Novel, Non-Opioid Asset for Osteoarthritis of the Knee
www.streetinsider.com - December 13 at 5:31 PM
Flexion Therapeutics Announces Acquisition of Novel, Non-Opioid Asset for Osteoarthritis of the KneeFlexion Therapeutics Announces Acquisition of Novel, Non-Opioid Asset for Osteoarthritis of the Knee
finance.yahoo.com - December 13 at 5:31 PM
Flexion Therapeutics (FLXN) Names Scott Kelley, MD as Chief Medical Officer - StreetInsider.comFlexion Therapeutics (FLXN) Names Scott Kelley, MD as Chief Medical Officer - StreetInsider.com
www.streetinsider.com - December 12 at 9:55 AM
Notable Monday Option Activity: KHC, RGLD, FLXNNotable Monday Option Activity: KHC, RGLD, FLXN
www.nasdaq.com - December 11 at 5:33 PM
Flexion Therapeutics Announces Appointment of Scott Kelley, M.D. as Chief Medical OfficerFlexion Therapeutics Announces Appointment of Scott Kelley, M.D. as Chief Medical Officer
finance.yahoo.com - December 11 at 5:33 PM
Critical Comparison: Flexion Therapeutics (FLXN) vs. Its RivalsCritical Comparison: Flexion Therapeutics (FLXN) vs. Its Rivals
www.americanbankingnews.com - December 9 at 8:02 AM
Flexion Therapeutics (FLXN) Enrolls First Patient in Phase 2 Pharmacokinetics and Safety Study of ZILRETTA - StreetInsider.comFlexion Therapeutics (FLXN) Enrolls First Patient in Phase 2 Pharmacokinetics and Safety Study of ZILRETTA - StreetInsider.com
www.streetinsider.com - December 7 at 5:48 PM
Flexion Therapeutics Enrolls First Patient in Phase 2 Pharmacokinetics and Safety Study of ZILRETTA™ (triamcinolone acetonide extended-release injectable suspension) in Bilateral Osteoarthritis of the KneeFlexion Therapeutics Enrolls First Patient in Phase 2 Pharmacokinetics and Safety Study of ZILRETTA™ (triamcinolone acetonide extended-release injectable suspension) in Bilateral Osteoarthritis of the Knee
finance.yahoo.com - December 7 at 5:48 PM
Flexion Therapeutics to Present at the BMO Capital Markets Prescriptions for Success Healthcare ConferenceFlexion Therapeutics to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference
finance.yahoo.com - December 6 at 5:23 PM
Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire (press release)Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire (press release)
globenewswire.com - December 5 at 10:10 AM
Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - December 4 at 5:20 PM
Flexion's (FLXN) Zilretta Therapy to Fast Capture OA MarketFlexion's (FLXN) Zilretta Therapy to Fast Capture OA Market
finance.yahoo.com - December 1 at 4:50 PM
Stock Traders Purchase Large Volume of Flexion Therapeutics Call Options (FLXN)Stock Traders Purchase Large Volume of Flexion Therapeutics Call Options (FLXN)
www.americanbankingnews.com - November 30 at 3:40 AM
Flexion Therapeutics Target of Unusually Large Options Trading (FLXN)Flexion Therapeutics Target of Unusually Large Options Trading (FLXN)
www.americanbankingnews.com - November 30 at 3:40 AM
Flexion Therapeutics to Present at Evercore ISI 2017 Biopharma Catalyst/Deep Dive ConferenceFlexion Therapeutics to Present at Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference
finance.yahoo.com - November 28 at 5:21 PM
This Small-Cap Biotech Stock Is Onto Something BigThis Small-Cap Biotech Stock Is Onto Something Big
finance.yahoo.com - November 28 at 9:05 AM
Notable Monday Option Activity: FLXN, VER, AVGONotable Monday Option Activity: FLXN, VER, AVGO
www.nasdaq.com - November 27 at 5:47 PM
Todays Research Reports on Stocks to Watch: Flexion Therapeutics and Teva PharmaceuticalToday's Research Reports on Stocks to Watch: Flexion Therapeutics and Teva Pharmaceutical
finance.yahoo.com - November 27 at 5:47 PM
Health Care Sector Update for 11/24/2017: FLXN,CYTX,MDGS - NasdaqHealth Care Sector Update for 11/24/2017: FLXN,CYTX,MDGS - Nasdaq
www.nasdaq.com - November 24 at 4:26 PM
Flexion Therapeutics, Inc. (FLXN) Receives Consensus Rating of "Buy" from BrokeragesFlexion Therapeutics, Inc. (FLXN) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - November 23 at 9:36 PM
Flexion Therapeutics, Inc. (FLXN) Insider Neil Bodick Purchases 2,700 SharesFlexion Therapeutics, Inc. (FLXN) Insider Neil Bodick Purchases 2,700 Shares
www.americanbankingnews.com - November 22 at 8:45 PM
Flexion Therapeutics (FLXN) Reports Full Commercial Launch ... - StreetInsider.comFlexion Therapeutics (FLXN) Reports Full Commercial Launch ... - StreetInsider.com
www.streetinsider.com - November 21 at 12:27 AM
Flexion Therapeutics Announces Full Commercial Launch and Nationwide Availability of ZILRETTA™ (triamcinolone acetonide extended-release injectable suspension)Flexion Therapeutics Announces Full Commercial Launch and Nationwide Availability of ZILRETTA™ (triamcinolone acetonide extended-release injectable suspension)
finance.yahoo.com - November 20 at 7:27 PM
Flexion Therapeutics Named Top Place to Work for 2017 by The​ ​Boston​ ​Globe​ - GlobeNewswire (press release)Flexion Therapeutics Named Top Place to Work for 2017 by The​ ​Boston​ ​Globe​ - GlobeNewswire (press release)
globenewswire.com - November 19 at 4:05 AM
Flexion Therapeutics Named Top Place to Work for 2017 by The​ ​Boston​ ​Globe​Flexion Therapeutics Named Top Place to Work for 2017 by The​ ​Boston​ ​Globe​
finance.yahoo.com - November 18 at 8:50 AM
Head to Head Comparison: Flexion Therapeutics (FLXN) & Its CompetitorsHead to Head Comparison: Flexion Therapeutics (FLXN) & Its Competitors
www.americanbankingnews.com - November 17 at 1:42 PM
Flexion Therapeutics, Inc. (FLXN) Expected to Post Quarterly Sales of $1.29 MillionFlexion Therapeutics, Inc. (FLXN) Expected to Post Quarterly Sales of $1.29 Million
www.americanbankingnews.com - November 14 at 9:02 AM
-$1.09 Earnings Per Share Expected for Flexion Therapeutics, Inc. (FLXN) This Quarter-$1.09 Earnings Per Share Expected for Flexion Therapeutics, Inc. (FLXN) This Quarter
www.americanbankingnews.com - November 12 at 8:38 AM
Short Interest in Flexion Therapeutics, Inc. (FLXN) Increases By 19.5%Short Interest in Flexion Therapeutics, Inc. (FLXN) Increases By 19.5%
www.americanbankingnews.com - November 11 at 3:40 AM
Flexion Therapeutics, Inc. (FLXN) Rating Reiterated by Northland SecuritiesFlexion Therapeutics, Inc. (FLXN) Rating Reiterated by Northland Securities
www.americanbankingnews.com - November 10 at 11:20 PM
Flexion Therapeutics Stock Sees Short Interest Jump 19.6%Flexion Therapeutics Stock Sees Short Interest Jump 19.6%
www.thestreet.com - November 10 at 4:40 PM
Michael D. Clayman Acquires 5,000 Shares of Flexion Therapeutics, Inc. (FLXN) StockMichael D. Clayman Acquires 5,000 Shares of Flexion Therapeutics, Inc. (FLXN) Stock
www.americanbankingnews.com - November 9 at 12:34 PM
Edited Transcript of FLXN earnings conference call or presentation 6-Nov-17 9:30pm GMTEdited Transcript of FLXN earnings conference call or presentation 6-Nov-17 9:30pm GMT
finance.yahoo.com - November 8 at 7:00 AM

SEC Filings

Flexion Therapeutics (NASDAQ:FLXN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Flexion Therapeutics (NASDAQ:FLXN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Flexion Therapeutics (NASDAQ FLXN) Stock Chart for Monday, February, 19, 2018

Loading chart…

This page was last updated on 2/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.